Victor Sandor - 17 Jun 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Director
Issuer ticker: PRLD
Reported as of: 17 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2022, 16:14:17 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 03 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Laurent Chardonnet, Attorney-in-Fact

Key filing fact

Victor Sandor filed Form 4 for Prelude Therapeutics Inc (PRLD) on 22 Jun 2022.

Key facts

This page summarizes Victor Sandor's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2022, 16:14.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +34,300
Change %
Price: $0.000000
Shares after: 34,300
Date: 17 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,300
Exercise price: $4.74
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.